Syndax Pharmaceuticals Inc — Director's Dealing 2021

Sep 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-09-13

Reporting Person: Metzger Michael A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-13	Common Stock	M	16651.00	$7.20	Acquired	34310.00	Direct
2021-09-13	Common Stock	S	16651.00	$19.0162	Disposed	17659.00	Direct
2021-09-14	Common Stock	M	44349.00	$7.20	Acquired	62008.00	Direct
2021-09-14	Common Stock	S	44349.00	$19.1525	Disposed	17659.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-13	Stock Options (Right to buy)	$7.20	M	16651.00	Disposed	2025-06-01	Common Stock (16651.00)	Direct
2021-09-14	Stock Options (Right to buy)	$7.20	M	44349.00	Disposed	2025-06-01	Common Stock (44349.00)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2: The sale prices ranged from $19.00 to $19.10

F3: The sale prices ranged from $19.00 to $19.31

F4: This option is fully vested.